Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 06:15 ET | Source: Alvotech

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin...
September 22, 2025 06:15 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
September 22, 2025 06:15 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
September 22, 2025 04:30 ET | Source: Alvotech

Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fyrirhugaðri hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab)

Mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hefur mælt með því að heimila markaðssetningu AVT05, sem er fyrirhuguð hliðstæða líftæknilyfsins Simponi (golimumab), sem þróuð var af Alvotech....
September 22, 2025 04:30 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
September 22, 2025 04:30 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
September 19, 2025 07:45 ET | Source: Alvotech

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
August 21, 2025 04:30 ET | Source: Alvotech

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
June 23, 2025 04:00 ET | Source: Alvotech

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...